Navigation Links
Access Pharmaceuticals Announces $2.7 Million New Equity
Date:1/29/2008

- Private Placement of Convertible Preferred Stock -

DALLAS, Jan. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it has executed agreements for $2.7 million in new equity. The Company has entered into agreements with institutional and accredited investors to purchase an aggregate of $2.7 million in gross proceeds of the Company's Series A Convertible Preferred Stock. This equity is in addition to the $9.5 million in gross proceeds announced in November 2007.

"We are excited to complete this placement of the Company's Series A Convertible Preferred Stock," said Jeffrey B. Davis, Access' CEO. "The additional new capital will enable us to fund a number of key objectives including pursuing and expanding our clinical trial program for Access' anti-cancer compound, ProLindac, a novel, proprietary DACH platinum which is currently in Phase 2 development."

Pursuant to the securities purchase agreements, the Company will, subject to the completion of the closing, issue to the new investors Series A Convertible Preferred Stock initially convertible into 908,000 shares of the Company's common stock. The investors will also receive warrants to purchase an additional 454,000 shares of the Company's common stock at an exercise price of $3.50. Upon closing, certain of the Company's Series A Convertible Preferred Stock will be amended.

Closing of the transaction is subject to the fulfillment of customary and usual closing conditions.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
2. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
3. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
4. Access Pharmaceuticals Announces $19.5 Million Recapitalization
5. Access Genetics Announces New Executive Appointments
6. Pharmasset Accesses up to $30 Million of Working Capital
7. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
8. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
9. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
10. Access Highlighted in Recent BusinessWeek Article
11. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 The Council for ... prestigious 2015 Borlaug CAST Communication Award goes to ... Tuskegee University in Alabama. Award nominees must demonstrate ... presentations; and/or the use of television, radio, or ... areas. As a specialist in the field of ...
(Date:4/16/2015)... Portage Biotech Inc. ("Portage" or "the Company" )) (OTC ... announce that the Company will be presenting  at the ... held in London, UK . Portage,s ... James Mellon , a director of Portage, will provide ... at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and Biohaven ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... A new infographic compiles useful information ... institutions to learn how Appleā€™s new framework can change ... is ideal since Apple made Research Kit ... open-source framework for developing medical research apps that Apple ... researchers to collect secure clinical data and communicate via ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Bioenterprise Corporation Expands into the Maritimes 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3
... N.J., Jan. 13 At the end of December,Trinitas ... treatment,centers in the state of New Jersey to offer ... Systems (NYSE: VAR ).,RapidArc is a fast, ... eight,times faster than is possible with conventional radiation therapy,technologies. ...
... Cumberland Pharmaceuticals Inc.,is pleased to announce the appointment ... Lee will draw upon his 24 years of pharmaceutical ... commercialization of,new products for the company. , ... "We are extremely pleased to ...
... a privately held development-stage biopharmaceutical company located in San ... President of Corporate Development, will present a corporate overview ... CA, on January 14, 2009 at 2:15pm. NexBio,s ... the quality of life by creating and commercializing novel, ...
Cached Biology Technology:Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3NexBio to Present at 2009 Biotech Showcase 2NexBio to Present at 2009 Biotech Showcase 3
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Center for Mitochondrial and Epigenomic Medicine at The ... Genetics Prize of The Gruber Foundation. This prestigious ... of the wide-ranging role of mitochondria in the ... evolution. Mitochondria are the tiny power plants ...
... Many lung cancers are driven by mutations in the ... that many successful modern treatments block EGFR activity. Unfortunately, ... lung cancers eventually relapse. A University of Colorado Cancer ... Research details a signaling pathway, known as ,the ...
... of tropical biologists congratulated Brazil for its global ... recent developments could jeopardize that position, undermining progress ... ecosystems outside the Amazon rainforest. Forgoing the ... conservationists met in Bonito, Brazil at the 49th ...
Cached Biology News:Dr. Douglas Wallace to receive Gruber Foundation 2012 Genetics Prize 2Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment 2Scientists warn Brazil's environmental leadership at risk 2Scientists warn Brazil's environmental leadership at risk 3
... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
... designed for RNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. Thousands ... synthesized on-chip and LC Sciences can provide ... are available as part of our comprehensive ...
... the C-terminal end of the mouse retinoic acid receptor beta (RAR*). ... of RAR*. The sequence of PEP-005 is (amino to carboxy terminus): ... S - S - V - E - N - S - ... L - L - Q (The N-terminal cysteine has been added ...
... ELx50 is a fast and versatile automated ... our patented Dual-ActionTM 16-channel manifold. This breakthrough ... dispense and aspiration manifolds for overfill washing ... 384-well formats. The problem of fitting dispense ...
Biology Products: